Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab

doi:10.3389/fimmu.2023.1131448

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/34871

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34871

题名:	Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab
作者:	Lin, Yun-Tzu Li, Chien-Feng Wu, Hung-Chang Jan, Yi-Hua Kuo, Yu-Hsuan
贡献者:	Chi Mei Med Ctr, Dept Oncol Chi Mei Med Ctr, Dept Pathol Natl Sun Yat sen Univ, Inst Precis Med Chi Mei Med Ctr, Dept Med Res Natl Inst Canc Res, Natl Hlth Res Inst Chia Nan Univ, Coll Pharm & Sci ACT Genom Co Ltd Institute of Biomedical Sciences, National Sun Yat-sen University
关键词:	SMARCA4 BRG1 SWI SNF lung cancer non-small cell lung carcinoma check-point inhibitors nivolumab
日期:	2023
上传时间:	2024-12-25 11:04:52 (UTC+8)
出版者:	FRONTIERS MEDIA SA
摘要:	SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma.
關聯:	Frontiers in Immunology, v.14, Article 1131448
显示于类别:	[Dept. of Pharmacy] Periodical Articles

文件中的档案:

档案	描述	大小	格式	浏览次数
fimmu.2023.1131448.pdf		2237Kb	Adobe PDF	206	检视/开启
index.html		0Kb	HTML	343	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....